BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
02 juin 2021 07h12 HE
|
BriaCell Therapeutics Corp.
12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors(1)Top Responder: 21.4 months survival plus 100%...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
19 mai 2021 17h15 HE
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
11 mai 2021 06h30 HE
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
21 avr. 2021 08h00 HE
|
Briacell Therapeutics Corp.
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics...
BriaCell Announces Investor and Media Outreach Programs
15 avr. 2021 18h00 HE
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
12 avr. 2021 13h45 HE
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
12 avr. 2021 06h30 HE
|
BriaCell Therapeutics Corp
Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset...
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
30 mars 2021 06h30 HE
|
BriaCell Therapeutics Corp
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American...
BriaCell Announces Closing of US$25 Million Public Offering
26 févr. 2021 14h24 HE
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing
23 févr. 2021 23h05 HE
|
BriaCell Therapeutics Corp
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage...